Alivus Life Sciences reported strong financial results for Q2FY26, with revenue growth of 16% YoY, reaching Rs. 5,880 Mn. EBITDA margins increased to 33.0%, a 480 bps YoY improvement. The company’s non-GPL business drove performance, growing by 39.7% YoY. Alivus maintains a positive outlook, expecting continued strength in the second half of the year.
Q2FY26 Financial Highlights
Alivus Life Sciences (formerly Glenmark Life Sciences Limited) announced its financial results for the quarter ended September 30, 2025 (Q2FY26), showcasing substantial growth.
- Revenue from operations: Rs. 5,880 Mn, up 16.0% YoY.
- EBITDA: Rs. 1,939 Mn, a 35.7% YoY increase.
- EBITDA margins: 33.0%, a significant rise of 480 bps YoY.
- PAT: Rs. 1,301 Mn, reflecting a 36.5% YoY growth.
- PAT margins: 22.1%, an increase of 330 bps YoY.
H1FY26 Performance Overview
The company also reported its performance for the half-year ended September 30, 2025 (H1FY26):
- Revenue from operations: Rs. 11,898 Mn, an increase of 8.6% YoY.
- EBITDA: Rs. 3,752 Mn, a growth of 21.9% YoY.
- EBITDA margins: 31.5%, up by 340 bps YoY.
- PAT: Rs. 2,516 Mn, up 21.7% YoY.
- PAT margins: 21.1%, an increase of 220 bps YoY.
Strong Cash Flow and Financial Position
During H1FY26, Alivus generated a strong free cash flow of Rs. 1,477 Mn, leading to cash and cash equivalents (including short-term investments) of Rs. 6,526 Mn as of September 30, 2025.
Key Growth Drivers
The company’s performance was driven by strong momentum in the non-GPL business, which grew by 39.7% YoY. Healthy demand across key geographies, including ROW, LATAM, Japan, Europe, and India, contributed to the overall performance.
Management Commentary
Dr. Yasir Rawjee, MD & CEO of Alivus Life Sciences Limited, commented on the company’s strong non-GPL business performance and expressed confidence in delivering a stronger performance in the second half of the year, supported by the non-GPL business and CDMO projects.
Tushar Mistry, CFO of Alivus Life Sciences Limited, highlighted the strong revenue growth of 16% in Q2FY26 and gross and EBITDA margins of 57.7% and 33% respectively. He also noted the successful maintenance of margins beyond their guidance, even without the PLI scheme benefits.
Capex and Expansion
The construction of Phase 1 at Solapur, for 200 KL capacity, is currently underway.
Source: BSE
